Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.

Cytometry B Clin Cytom 2016 Jan 31;90(1):91-100. Epub 2015 Jul 31.

Centro de Investigación del Cáncer (Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL), Instituto Biosanitario de Salamanca (IBSAL), Servicio General de Citometría y Departamento De Medicina (NUCLEUS), Universidad de Salamanca (Salamanca), Spain.

Background: Multiparameter flow cytometry (MFC) identification and characterization of plasma cells (PCs) is a useful tool to support diagnosis, prognostication, and monitoring of PC diseases (PCD). Currently, the number of MFC markers suited for the identification of PC remains limited. Moreover, antibody therapies against PC-associated markers further compromise the utility of the most widely used reagents (e.g., CD38). Despite markers other than CD38 and CD138 are recognized as potentially useful PC-identification markers, no study has comparatively evaluated their performance in combination with CD38 and CD138. Here we compared the utility of CD229, CD54, and CD319 for the identification of normal and aberrant PCs.

Methods: Bone marrow (BM) samples from 5 healthy controls, two noninfiltrated nonHodgkin lymphoma cases and 46 PCD patients plus 3 extraosseous plasmocytomas, and normal peripheral blood (PB) specimens, were studied.

Results: Our results showed adequate performance of all three markers once combined with CD38. In contrast, when combined with CD138 for the identification of PC, only CD229 provided a good discrimination between PCs and all other cells for all BM and PB samples analyzed; in contrast, CD54 and CD319 showed limited utility for the identification of PCs, mainly because of significant overlap of the staining for these two markers on PCs and other myeloid cells in the sample.

Conclusions: From the three markers evaluated, CD229 may be considered as the most reliable marker to replace CD38 or CD138 for the identification of PCs in patients undergoing anti-CD38 or anti-CD138 therapy, until a better alternative is available.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21269DOI Listing
January 2016
31 Reads

Publication Analysis

Top Keywords

cd38 cd138
12
plasma cells
8
three markers
8
cd138 identification
8
identification pcs
8
cd319 identification
8
cd54 cd319
8
markers
7
identification
7
pcs
5
cd38
5
plasmocytomas normal
4
extraosseous plasmocytomas
4
lymphoma cases
4
cases pcd
4
pcd patients
4
patients extraosseous
4
normal peripheral
4
peripheral blood
4
cd54 cd229
4

References

(Supplied by CrossRef)

McKenna et al.
2008
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders
Paiva et al.
Cytometry B Clin Cytom 2010
Potential role of daratumumab in the treatment of multiple myeloma
Khagi et al.
Onco Targets Ther 2014

Similar Publications